Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 1:22 pm Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | PRICE T ROWE ASSOCIATES INC | 6,601,141 10.800% | 1,504,354 (+29.52%) | View |
| 2024-11-12 10:32 am Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | FMR LLC | 5,101,413 8.312% | -435,826 (-7.87%) | View |
| 2024-10-30 5:10 pm Sale | 13D | Monte Rosa Therapeutics Inc. GLUE | Versant Venture Capital VI L.P. | 4,079,469 6.600% | -1,019,867 (-20.00%) | View |
| 2024-09-24 5:00 pm Sale | 13D | Monte Rosa Therapeutics Inc. GLUE | Versant Venture Capital VI L.P. | 5,099,336 8.300% | -1,699,779 (-25.00%) | View |
| 2024-08-12 7:46 pm Sale | 13D | Monte Rosa Therapeutics Inc. GLUE | New Enterprise Associates 17 L.P. | 7,774,930 12.700% | -10,000 (-0.13%) | View |
| 2024-08-12 5:07 pm Unchanged | 13D | Monte Rosa Therapeutics Inc. GLUE | Versant Venture Capital VI L.P. | 6,799,115 11.100% | 0 (Unchanged) | View |
| 2024-05-13 8:40 pm Purchase | 13D | Monte Rosa Therapeutics Inc. GLUE | New Enterprise Associates 17 L.P. | 7,784,930 15.400% | 7,784,930 (New Position) | View |
| 2024-04-10 12:58 pm Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | PRICE T ROWE ASSOCIATES INC | 5,096,787 10.200% | 155,080 (+3.14%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | BAKER BROS. ADVISORS LP | 4,916,095 9.800% | 4,916,095 (New Position) | View |
| 2024-02-14 3:02 pm Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | Cormorant Asset Management LP | 0 0.000% | -2,893,717 (Position Closed) | View |
| 2024-02-14 11:22 am Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | BlackRock Inc. BLK | 2,371,980 4.700% | -1,226,556 (-34.08%) | View |
| 2024-02-14 10:03 am Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | PRICE T ROWE ASSOCIATES INC | 4,941,707 9.900% | 1,258,277 (+34.16%) | View |
| 2024-02-14 09:14 am Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | Avoro Capital Advisors LLC | 4,535,000 9.100% | 210,000 (+4.86%) | View |
| 2024-02-09 09:28 am Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | FMR LLC | 5,537,239 11.056% | -680,219 (-10.94%) | View |
| 2023-11-09 5:26 pm Unchanged | 13D | Monte Rosa Therapeutics Inc. GLUE | Versant Venture Capital VI L.P. | 6,799,115 13.700% | 0 (Unchanged) | View |
| 2023-02-14 3:11 pm Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | Cormorant Asset Management LP | 2,893,717 5.980% | -108,483 (-3.61%) | View |
| 2023-02-14 12:38 pm Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | PRICE T ROWE ASSOCIATES INC | 3,683,430 7.600% | -1,175,197 (-24.19%) | View |
| 2023-02-14 09:40 am Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | Avoro Capital Advisors LLC | 4,325,000 8.900% | 1,013,566 (+30.61%) | View |
| 2023-02-09 12:01 pm Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | FMR LLC | 6,217,458 12.846% | -758,429 (-10.87%) | View |
| 2023-02-03 4:27 pm Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | BlackRock Inc. BLK | 3,598,536 7.400% | 2,006,738 (+126.07%) | View |